ersodetug — Regulatory decision
H2 2026
We expect to have an update on the program in the second half of 2026.Source filing
RZLT biotech catalysts & pipeline
REZOLUTE INC · Data as of 2026-10-25
Upcoming catalysts
ersodetug — Topline data
this quarter
On track to report topline results for the Phase 3 upLIFT study in tumor HI this quarterSource filing
ersodetug — Topline data
Dec 2026
Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced that the open-label Phase 3 study of ersodetug in tumor HI (upLIFT) is now fully enrolled and topline data are expected mid-December 2026.Source filing